Finance Monthly CFO Awards 2019 Winners Edition

www.finance-monthly.com 42 Finance Monthly CFO Awards 2019 CFO of Novartis HARRY KIRSCH ABOUT HARRY KIRSCH Harry Kirsch has been Chief Financial Officer (CFO) of Novartis since 2013. He is a member of the Executive Committee of Novartis. Mr. Kirsch joined Novartis in 2003 and, prior to his current position, served as CFO of the Pharmaceuticals Division (now known as the Innovative Medicines Division). He has been instrumental in focusing Novartis as a leading medicines company by overseeing key divestitures, the acquisition of GlaxoSmithKline’s oncology products in 2015, and the spin of Alcon into a public company in 2019. In prior assignments, he served as CFO of Pharma Europe and as Business Planning & Analysis Head of the Pharmaceuticals Division. Mr. Kirsch joined Novartis from Procter & Gamble (P&G) in the United States, where he was CFO of P&G’s global pharmaceutical business. Prior to that, he held finance positions in various categories of P&G’s consumer goods business, technical operations and Global Business Services organization. Mr. Kirsch holds a diploma degree in industrial engineering and economics from the University of Karlsruhe in Germany. From 2015 to 2018, he represented Novartis on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd. FIRM PROFILE Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, it is one of the largest pharmaceutical companies by both market capitalization and sales. Our purpose is to reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company. Novartis is structured to deliver innovative products, exploit global scale, and respond to new opportunities and risks. Our divisions - Innovative Medicines and Sandoz - are supported by functional organizations with global scale. Our researchers combine imagination with the rigor of collaborative science to find better treatments for disease. We collaborate across scientific and organizational boundaries to engage powerful new technologies that have the potential to produce breakthroughs for people worldwide. www.novartis.co.uk FACTS & FIGURES 155 Countries in which products are available 200+ Projects in the clinical pipeline 500+ Clinical trials in progress Finance Monthly CFO Awards 2019 SWITZERLAND